Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
2017 · BMC Neurology · 209 citations
https://doi.org/10.1186/s12883-017-0790-9
A
Amy Pasternak
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
89
Papers
3.7K
Citations
29
h-index
46
i10-index
Amy Pasternak is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Neurogenetic and Muscular Disorders Research & Muscle Physiology and Disorders & Congenital Anomalies and Fetal Surgery. The author has an h-index of 29, co-authored 76 publications.
ORCID: 0000-0001-8841-2613Papers by this author
worksRevised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
2017 · PLoS ONE · 157 citations
https://doi.org/10.1371/journal.pone.0172346
Revised upper limb module for spinal muscular atrophy: 12 month changes
2019 · Muscle & Nerve · 142 citations
https://doi.org/10.1002/mus.26419
Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
2019 · Muscle & Nerve · 87 citations
https://doi.org/10.1002/mus.26633
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
2021 · Neurology Clinical Practice · 71 citations
https://doi.org/10.1212/cpj.0000000000001033
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
2023 · Neurology and Therapy · 53 citations
https://doi.org/10.1007/s40120-023-00444-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat